The present invention relates to novel esterases, more particularly to esterases having improved activity and/or improved thermostability compared to a parent esterase. The present invention also relates to uses of said novel esterases for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and polyethylene terephthalate containing material.

BACKGROUND

Esterases are able to catalyze the hydrolysis of a variety of polymers, including polyesters. In this context, esterases have shown promising effects in a number of industrial applications, including as detergents for dishwashing and laundry applications, as degrading enzymes for processing biomass and food, as biocatalysts in detoxification of environmental pollutants or for the treatment of polyester fabrics in the textile industry. The use of esterases as degrading enzymes for hydrolyzing polyethylene terephthalate (PET) is of particular interest. Indeed, PET is used in a large number of technical fields, such as in the manufacture of clothes, carpets, or in the form of a thermoset resin for the manufacture of packaging or automobile plastics, etc., so that PET accumulation in landfills becomes an increasing ecological problem.

The enzymatic degradation of polyesters, and particularly of PET, is considered as an interesting solution to decrease plastic waste accumulation. Indeed, enzymes may accelerate hydrolysis of polyester containing material, and more particularly of plastic products, even up to the monomer level. Furthermore, the hydrolysate (i.e., monomers and oligomers) can be recycled as material for synthesizing new polymers.

In this context, several esterases have been identified as candidate degrading enzymes for polyesters, and some variants of such esterases have been developed. Among esterases, cutinases, also known as cutin hydrolases (EC 3.1.1.74), are of particular interest. Cutinases have been identified from various fungi (P.E. Kolattukudy in "Lipases", Ed. B. Borg- strom and H.L. Brockman, Elsevier 1984, 471-504), bacteria and plant pollen. Recently, metagenomics approaches have led to identification of additional esterases.

However, there is still a need for esterases with improved activity and/or improved thermostability compared to already known esterases, to provide polyester degrading processes more efficient and thereby more competitive. SUMMARY OF THE INVENTION

The present invention provides new esterases exhibiting increased activity and/or increased thermostability compared to a parent, or wild-type esterase, having the amino acid sequence as set forth in SEQ ID N°l. This wild-type esterase corresponds to the esterase referenced as UPI0007C1BBA7 in UniParc database and described as having a polyester degrading activity. The esterases of the present invention are particularly useful in processes for degrading plastic products, more particularly plastic products containing PET.

In this regard, it is an object of the invention to provide an esterase which (i) has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the full length amino acid sequence set forth in SEQ ID N°l, and (ii) has at least one amino acid substitution at a position corresponding to residues selected from T12, E13, S14, S15, 116, E17, A18, V19, R20, R32, A35, F38, G62, F63, T64, A65, G66, Q67, E68, S69, 170, A71, W72, P75, R76, D88, T89, R92, L93, D94, Q95, P96, D97, H130, M132, G133, S139, W156, T158, R159, V172, Q175, T178, 1179, A180, P 181 , S184, F189, L204, R205, G206, A207, S208, V211, S212, N213, T214, P215, D216, T217, T218, T219, A220, K221, Y222, Q239, F240, L241, P243, A244, P245, D246, D247, F248, A249, 1250, S251, G136, T169 wherein the positions are numbered by reference to the amino acid sequence set forth in SEQ ID N°l, and (iii) exhibits increased polyester degrading activity and/or an increased thermostability compared to an esterase of SEQ ID N° 1.

It is another object of the invention to provide an esterase which (i) has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the full length amino acid sequence set forth in SEQ ID N°l, and (ii) has at least one amino acid substitution at position L210 wherein the position is numbered by reference to the amino acid sequence set forth in SEQ ID N°l, and wherein the substitution is different from L210F.

It is another object of the invention to provide an esterase which (i) has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the full length amino acid sequence set forth in SEQ ID N°l, (ii) contains at least one amino acid substitution selected from L210 A/C/D/E/ G/FEI/K/M/N/P/ Q/R/ S/T/V/W /Y, R205C, S251C, Q95G/P, G136A, T169Q, VI 721, S184E or N213M/D wherein the position is numbered by reference to the amino acid sequence set forth in SEQ ID N° 1.

Preferably, the esterase comprises at least one substitution or combination of substitutions selected from L210T/A/R/W/H or R205C + S251C, preferably L210T. In a particular embodiment, the esterase comprises at least the combination of substitution L210T + VI 721. Preferably, the esterase further comprises at least one amino acid residue selected from S131, D177 and H209, preferably the combination S131 + D177 + H209.

It is another object of the invention to provide a nucleic acid encoding an esterase of the invention. The present invention also relates to an expression cassette or an expression vector comprising said nucleic acid, and to a host cell comprising said nucleic acid, expression cassette or vector.

The present invention also provides a composition comprising an esterase of the present invention, a host cell of the present invention, or extract thereof.

It is a further object of the invention to provide a method of producing an esterase of the invention comprising:

(a) culturing the host cell according to the invention under conditions suitable to express a nucleic acid encoding an esterase; and optionally

(b) recovering said esterase from the cell culture.

It is a further object of the invention to provide a method of degrading a polyester comprising (a) contacting the polyester with an esterase according to the invention or a host cell according to the invention or a composition according to the invention; and, optionally

(b) recovering monomers and/or oligomers.

Particularly, the invention provides a method of degrading PET, comprising contacting PET with at least one esterase of the invention, and optionally recovering monomers and/or oligomers of PET.

The present invention also relates to a method of degrading at least one polyester of a polyester containing material comprising the following steps:

(a) contacting the polyester containing material with an esterase or host cell according to the invention, thereby degrading at least one polyester of the polyester containing material; and optionally

(b) recovering monomers and/or oligomers of said at least one polyester. The invention also relates to the use of an esterase of the invention for degrading PET or a plastic product containing PET.

The present invention also relates to a polyester containing material in which an esterase or a host cell or a composition of the invention is included.

The present invention also relates to a detergent composition comprising the esterase or host cell according to the invention or a composition comprising an esterase of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

The present disclosure will be best understood by reference to the following definitions.

Herein, the terms“ peptide”,“ polypeptide”,“ protein”,“ enzyme” refer to a chain of amino acids linked by peptide bonds, regardless of the number of amino acids forming said chain. The amino acids are herein represented by their one-letter or three-letters code according to the following nomenclature: A: alanine (Ala); C: cysteine (Cys); D: aspartic acid (Asp); E: glutamic acid (Glu); F: phenylalanine (Phe); G: glycine (Gly); H: histidine (His); I: isoleucine (He); K: lysine (Lys); L: leucine (Leu); M: methionine (Met); N: asparagine (Asn); P: proline (Pro); Q: glutamine (Gin); R: arginine (Arg); S: serine (Ser); T: threonine (Thr); V: valine (Val); W: tryptophan (Trp ) and Y : tyrosine (Tyr).

The term“ esterase” refers to an enzyme which belongs to a class of hydrolases classified as EC 3.1.1 according to Enzyme Nomenclature that catalyzes the hydrolysis of esters into an acid and an alcohol. The term“cutinase” or“ cutin hydrolase” refers to the esterases classified as EC 3.1.1.74 according to Enzyme Nomenclature that are able to catalyse the chemical reaction of production of cutin monomers from cutin and water.

The terms“ wild-type protein” or“ parent protein” refer to the non-mutated version of a polypeptide as it appears naturally. In the present case, the parent esterase refers to the esterase having the amino acid sequence as set forth in SEQ ID N°l .

The terms“ mutant” and“ variant’ refer to polypeptides derived from SEQ ID N°1 and comprising at least one modification or alteration, i.e., a substitution, insertion, and/or deletion, at one or more (e.g., several) positions and having a polyester degrading activity. The variants may be obtained by various techniques well known in the art. In particular, examples of techniques for altering the DNA sequence encoding the wild-type protein, include, but are not limited to, site-directed mutagenesis, random mutagenesis and synthetic oligonucleotide construction. Thus, the terms“ modification” and“ alteration” as used herein in relation to a particular position means that the amino acid in this particular position has been modified compared to the amino acid in this particular position in the wild-type protein.

A“ substitution” means that an amino acid residue is replaced by another amino acid residue. Preferably, the term“substitution” refers to the replacement of an amino acid residue by another selected from the naturally-occurring standard 20 amino acid residues, rare naturally occurring amino acid residues (e.g. hydroxyproline, hydroxylysine, allohydroxylysine, 6-N-methylysine, N-ethylglycine, N-methylglycine, N-ethylasparagine, allo-isoleucine, N-methylisoleucine, N- methylvaline, pyroglutamine, aminobutyric acid, ornithine, norleucine, norvaline), and non- naturally occurring amino acid residue, often made synthetically, (e.g. cyclohexyl-alanine). Preferably, the term“ substitution” refers to the replacement of an amino acid residue by another selected from the naturally-occurring standard 20 amino acid residues (G, P, A, V, L, I, M, C, F, Y, W, H, K, R, Q, N, E, D, S and T). The sign“+” indicates a combination of substitutions. In the present document, the following terminology is used to designate a substitution: L82A denotes that amino acid residue (Leucine, L) at position 82 of the parent sequence is substituted by an Alanine (A). A121 V/I/M denotes that amino acid residue (Alanine, A) at position 121 of the parent sequence is substituted by one of the following amino acids: Valine (V), Isoleucine (I), or Methionine (M). The substitution can be a conservative or non-conservative substitution. Examples of conservative substitutions are within the groups of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine, asparagine and threonine), hydrophobic amino acids (methionine, leucine, isoleucine, cysteine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine and serine).

Unless otherwise specified, the positions disclosed in the present application are numbered by reference to the amino acid sequence set forth in SEQ ID N°l .

As used herein, the term“ sequence identity’’ or“ identity” refers to the number (or fraction expressed as a percentage %) of matches (identical amino acid residues) between two polypeptide sequences. The sequence identity is determined by comparing the sequences when aligned so as to maximize overlap and identity while minimizing sequence gaps. In particular, sequence identity may be determined using any of a number of mathematical global or local alignment algorithms, depending on the length of the two sequences. Sequences of similar lengths are preferably aligned using a global alignment algorithm (e.g. Needleman and Wunsch algorithm; Needleman and Wunsch, 1970) which aligns the sequences optimally over the entire length, while sequences of substantially different lengths are preferably aligned using a local alignment algorithm (e.g. Smith and Waterman algorithm (Smith and Waterman, 1981) or Altschul algorithm (Altschul et al., 1997; Altschul et al., 2005)). Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software available on internet web sites such as http://blast.ncbi.nlm.nih.gov/ or http://www.ebi.ac.uk/Tools/emboss/). Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, % amino acid sequence identity values refers to values generated using the pair wise sequence alignment program EMBOSS Needle that creates an optimal global alignment of two sequences using the Needleman-Wunsch algorithm, wherein all search parameters are set to default values, i.e. Scoring matrix = BLOSUM62, Gap open = 10, Gap extend = 0.5, End gap penalty = false, End gap open = 10 and End gap extend = 0.5.

A“ polymer” refers to a chemical compound or mixture of compounds whose structure is constituted of multiple monomers (repeat units) linked by covalent chemical bonds. Within the context of the invention, the term polymer includes natural or synthetic polymers, constituted of a single type of repeat unit (i.e., homopolymers) or of a mixture of different repeat units (i.e., copolymers or heteropolymers). According to the invention,“ oligomers” refer to molecules containing from 2 to about 20 monomers.

In the context of the invention, a“ polyester containing materiaF or“ polyester containing product’ refers to a product, such as plastic product, comprising at least one polyester in crystalline, semi-crystalline or totally amorphous forms. In a particular embodiment, the polyester containing material refers to any item made from at least one plastic material, such as plastic sheet, tube, rod, profile, shape, film, massive block, etc., which contains at least one polyester, and possibly other substances or additives, such as plasticizers, mineral or organic fillers. In another particular embodiment, the polyester containing material refers to a plastic compound, or plastic formulation, in a molten or solid state, suitable for making a plastic product. In another particular embodiment, the polyester containing material refers to textile, fabrics or fibers comprising at least one polyester. In another particular embodiment, the polyester containing material refers to plastic waste or fiber waste comprising at least one polyester.

In the present description, the term “ polyester (s)” encompasses but is not limited to polyethylene terephthalate (PET), polytrimethylene terephthalate (PTT), polybutylene terephthalate (PBT), polyethylene isosorbide terephthalate (PEIT), polylactic acid (PLA), polyhydroxyalkanoate (PHA), polybutylene succinate (PBS), polybutylene succinate adipate (PBS A), polybutylene adipate terephthalate (PBAT), polyethylene furanoate (PEF), polycaprolactone (PCL), poly(ethylene adipate) (PEA) , polyethylene naphthalate (PEN) and blends/mixtures of these polymers.

New esterases

The present invention provides novel esterases with improved activity and/or improved thermostability compared to a parent esterase. More particularly, the inventors have designed novel enzymes particularly suited for use in industrial processes. The esterases of the invention are particularly suited to degrade polyesters, more particularly PET, including PET containing material and particularly plastic product containing PET. In a particular embodiment, the esterases exhibit both an increased activity and an increased thermostability.

It is therefore an object of the present invention to provide esterases that exhibit an increased activity, compared to the esterase having the amino acid sequence as set forth in SEQ ID N°l .

Particularly, the inventors have identified specific amino acid residues in SEQ ID N° l, which are intended to be in contact with a polymer substrate in the X-ray crystal structure (i.e., folded 3D structure) of the esterases that may be advantageously modified to promote the contact of the substrate with the esterases and leading to an increased adsorption of the polymer and/or thereby to an increased activity of the esterases on this polymer.

Within the context of the invention, the term“increased activity” or“increased degrading activity” indicates an increased ability of the esterase to degrade a polyester and/or an increased ability to adsorb on a polyester, at a given temperature as compared to the ability of the esterase of SEQ ID N°1 to degrade and/or adsorb on same polyester at same temperature. Particularly, the esterase of the invention has an increased PET degrading activity. Such an increase may be at least 10% greater than the PET degrading activity of the esterase of SEQ ID N°l, preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130% or greater. Particularly, the degrading activity is a depolymerization activity leading to monomers and/or oligomers of the polyester, which can be further retrieved and optionally reused.

The“degrading activity” of an esterase may be evaluated by the one skilled in the art, according to methods known per se in the art. For instance, the degrading activity can be assessed by measurement of the specific polymer’s depolymerization activity rate, the measurement of the rate to degrade a solid polymer compound dispersed in an agar plate, or the measurement of the polymer’s depolymerization activity rate in reactor. Particularly, the degrading activity may be evaluated by measuring the“specific degrading activity” of an esterase. The“specific degrading activity” of an esterase for PET corresponds to pmol of PET hydrolyzed/min or mg of equivalent TA produced/hour and per mg of esterase during the initial period of the reaction (i.e. the first 24 hours) and is determined from the linear part of the hydrolysis curve of the reaction, such curve being set up by several samplings performed at different time during the first 24 hours. As another example, the“degrading activity” may be evaluated by measuring, after a defined period of time, the rate and/or yield of oligomers and/or monomers released under suitable conditions of temperature, pH and buffer, when contacting the polymer or the polymer-containing plastic product with a degrading enzyme.

The ability of an enzyme to adsorb on a substrate may be evaluated by the one skilled in the art, according to methods known per se in the art. For instance, the ability of an enzyme to adsorb on a substrate can be measured from a solution containing the enzyme and wherein the enzyme has been previously incubated with a substrate under suitable conditions.

The inventors have also identified target amino acid residues in SEQ ID N°l, that may be advantageously modified to improve the stability of corresponding esterases at high temperatures (i.e., improved thermostability), and advantageously at temperature above 60°C, preferably above 70°C.

It is therefore an object of the present invention to provide new esterases that exhibit increased thermostability as compared to the thermostability of the esterase having the amino acid sequence set forth in SEQ ID N° 1.

Within the context of the invention, the term“increased thermostability” indicates an increased ability of an esterase to resist to changes in its chemical and/or physical structure at high temperatures, and particularly at temperature between 40°C and 80°C, as compared to the esterase of SEQ ID N° 1.

Particularly, the thermostability may be evaluated through the assessment of the melting temperature (Tm) of the esterase. In the context of the present invention, the “melting temperature” refers to the temperature at which half of the enzyme population considered is unfolded or misfolded. Typically, esterases of the invention show an increased Tm of about 1°C, 2°C, 3°C, 4°C, 5°C, 10°C or more, as compared to the Tm of the esterase of SEQ ID N°l. In particular, esterases of the present invention can have an increased half-life at a temperature between 40°C and 80°C, as compared to the esterase of SEQ ID N°l . The melting temperature (Tm) of an esterase may be measured by the one skilled in the art, according to methods known per se in the art. For instance, the DSF may be used to quantify the change in thermal denaturation temperature of the esterase and thereby to determine its Tm. Alternatively, the Tm can be assessed by analysis of the protein folding using circular dichroism. Preferably, the Tm is measured using DSF or circular dichroism as exposed in the experimental part. In the context of the invention, comparisons of Tm are performed with Tm that are measured under same conditions (e.g. pH, nature and amount of polyesters, etc.).

Alternatively, the thermostability may be evaluated by measuring the esterase activity and/or the polyester depolymerization activity of the esterase after incubation at different temperatures and comparing with the esterase activity and/or polyester depolymerization activity of the parent esterase. The ability to perform multiple rounds of polyester’s depolymerization assays at different temperatures can also be evaluated. A rapid and valuable test may consist on the evaluation, by halo diameter measurement, of the esterase ability to degrade a solid polyester compound dispersed in an agar plate after incubation at different temperatures.

It is thus an object of the present invention to provide an esterase which (i) has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the full length amino acid sequence set forth in SEQ ID N°l, (ii) contains at least one amino acid substitution at a position corresponding to residues selected from the group consisting of T12, E13, S14, S15, 116, E17, A18, V19, R20, R32, A35, F38, G62, F63, T64, A65, G66, Q67, E68, S69, 170, A71, W72, P75, R76, D88, T89, R92, L93, D94, Q95, P96, D97, H130, M132, G133, S139, W156, T158, R159, V172, Q175, T178, 1179, A180, P181, S184, F189, L204, R205, G206, A207, S208,

V211, S212, N213, T214, P215, D216, T217, T218, T219, A220, K221, Y222, Q239, F240,

L241, P243, A244, P245, D246, D247, F248, A249, 1250, S251, G136, T169 as compared to the amino acid sequence SEQ ID N°l, and (iii) exhibits increased polyester degrading activity and/or increased thermostability as compared to the esterase of SEQ ID N°l .

In a particular embodiment, the esterase contains at least one amino acid substitution at a position corresponding to residues selected from the group consisting of T12, E13, S14, S15, 116, E17, A18, V19, R20, R32, A35, F38, G62, F63, T64, A65, G66, Q67, E68, S69, 170, A71, W72, P75, R76, D88, T89, R92, L93, D94, Q95, P96, D97, H130, M132, G133, S139, W156, T158, R159, V172, Q175, T178, 1179, A180, P181, S184, F189, L204, R205, G206, A207,

S208, V211, S212, N213, T214, P215, D216, T217, T218, T219, A220, K221, Y222, Q239,

F240, L241, P243, A244, P245, D246, D247, F248, A249, 1250 or S251.In an embodiment, the esterase contains at least one amino acid substitution at a position corresponding to residues selected from the group consisting of G136 or T169. Unless otherwise specified, the positions disclosed in the present application are numbered by reference to the amino acid sequence set forth in SEQ ID N°l .

According to the invention, the targeted amino acid(s) may be replaced by any one of the 19 other amino acids.

In a particular embodiment, the esterase has the amino acid sequence set forth in SEQ ID N°1 with a single amino acid substitution at a position corresponding to residues selected from T12, E13, S14, S15, 116, E17, A18, V19, R20, R32, A35, F38, G62, F63, T64, A65, G66, Q67, E68, S69, 170, A71, W72, P75, R76, D88, T89, R92, L93, D94, Q95, P96, D97, H130, M132, G133, S139, W156, T158, R159, V172, Q175, T178, 1179, A180, P181, S184, F189, L204, R205, G206, A207, S208, V211, S212, N213, T214, P215, D216, T217, T218, T219, A220, K221, Y222, Q239, F240, L241, P243, A244, P245, D246, D247, F248, A249, 1250, S251, G136 or T169. Particularly, the esterase has the amino acid sequence set forth in SEQ ID N°1 with a single amino acid substitution at a position corresponding to residues selected from T12, E13, S14, S15, 116, E17, A18, V19, R20, R32, A35, F38, G62, F63, T64, A65, G66, Q67, E68, S69, 170, A71, W72, P75, R76, D88, T89, R92, L93, D94, Q95, P96, D97, H130, M132, G133, S139, W156, T158, R159, V172, Q175, T178, 1179, A180, P181, S184, F189, L204, R205, G206, A207, S208, V211, S212, N213, T214, P215, D216, T217, T218, T219, A220, K221, Y222, Q239, F240, L241, P243, A244, P245, D246, D247, F248, A249, 1250 or S251. Preferably, the esterase comprises a single substitution at a position corresponding to residues selected from Q95, V172, S184, R205, N213 and S251, preferably a single substitution selected from Q95G/P, VI 721, S184E, R205C, N213M/D and S251C. More preferably, the esterase comprises a single substitution at a position corresponding to residues selected from Q95, VI 72, S184, and N213, preferably a single substitution selected from Q95G/P, V172I, S184E, or N213M/D. Alternatively, the esterase has the amino acid sequence set forth in SEQ ID N°1 with a single amino acid substitution at a position corresponding to residues selected from G136 or T169, preferably a single substitution selected from G136A and T169Q.

In an embodiment of the invention, the esterase comprises a least one substitution at a position corresponding to residues selected from T12, E13, S14, S15, 116, E17, A18, V19, R20, G62, F63, T64, A65, G66, Q67, E68, S69, 170, A71, W72, P75, R76, D88, T89, R92, L93, D94, Q95, P96, D97, H130, M132, G133, S139, W156, T158, R159, V172, T178, 1179, A180, P181, S184, FI 89, L204, G206, A207, S208, V211, S212, N213, T214, P215, D216, T217, T218, T219, A220, K221, Y222, Q239, F240, L241, P243, A244, P245, D246, D247, F248, A249 or 1250. Preferably, the esterase comprises a least one substitution at a position corresponding to residues selected from Q95, V172, S184 and N213. Preferably said at least one substitution is selected from Q95G/P, VI 721, S184E and N213D/M.

In an embodiment of the invention, the esterase comprises a least one substitution at a position corresponding to residues selected from R32, A35 or F38.

In an embodiment of the invention, the esterase comprises a least one substitution at a position corresponding to residues selected from Q175, 1179, R205, G206 or S251. In a particular embodiment, the esterase comprises a least one substitution at a position Q175 and exhibits an increased activity as compared to the esterase of SEQ ID N°l . In another particular embodiment, the esterase comprises a least one substitution at a position selected from 1179 or G206 and exhibits an increased thermostability as compared to the esterase of SEQ ID N° 1. In an embodiment, the esterase comprises a least a combination of substitution at positions R205 + S251, preferably at least the combination of substitutions R205C + S251C. In a preferred embodiment, the esterase comprises the combination of substitutions R205C + S251C and exhibits an increased thermostability as compared to the esterase of SEQ ID N° 1.

In a particular embodiment, the esterase comprises at least one amino acid substitution at a position corresponding to residues selected from the group consisting of G136 or T169. Particularly, the esterase comprises at least one substitution selected from G136A or T169Q.

In an embodiment, the esterase comprises at least one substitution at position selected from T64, E68, Q95, V172, N213, P215, G136, S184 or T169. Particularly, the esterase comprises at least one substitution selected from T64M, E68T, Q95G/P, V172I, N213D/M, P215D, G136A, S184E or T169Q. Preferably, the esterase comprises at least one substitution at position selected from T64, E68, Q95, V172, N213 or P215, particularly selected from T64M, E68T, Q95G/P, VI 721 or N213D/M. More preferably, the esterase comprises at least one substitution at position VI 72, preferably VI 721.

In a preferred embodiment, the esterase further comprises at least one substitution at position L210 more preferably selected from L210T/A/R/W/H/F, even more preferably L210T. In an embodiment, the esterase further comprises the substitution L210F. Particularly, the esterase of the invention comprises at least one combination of substitutions at position selected from L210 + R205 + S251, preferably selected from L210T/A/R/W/H/F + R205C + S251C, more preferably L210T + R205C + S251C. In an embodiment, the esterase comprises an amino acid sequence consisting of the amino acid sequence set forth in SEQ ID N°1 with the combination of substitutions L210T + R205C + S251C. In an embodiment, the esterase comprises at least one substitution at position VI 72 and at least one substitution at position selected from Q95, N213, G136, T169, S184 or L210. Preferably, the esterase comprises at least the substitution VI 721 and at least one substitution selected from Q95G/P, N213D/M, G136A, T169Q, S184E or L210T/A/R/W/H/F.

Particularly, the esterase comprises at least one combination of substitutions at positions L210 + V172, preferably at least one combination of substitutions selected from L210T/A/R/W/H/F + VI 721, more preferably L210T + VI 721.

In a particular embodiment, the esterase comprises at least a combination of substitutions selected from L210T/A/R/W/H/F + V172I and at least one substitution at T64, E68, Q95, N213, P215, G136, T169 or S184, preferably selected from T64M, E68T, Q95G/P, N213D/M, G136A, T169Q, S184E.

In an embodiment, the esterase comprises at least one combination of substitutions selected from L210 + V172 + Q95, L210 + V172 + Q95 + S184, L210 + V172 + N213 or L210 + V172 + Q95 + G136 + T169 + S184. Particularly, the esterase comprises at least one combination of substitutions selected from L210T + VI 721 + Q95G, L210T + VI 721 + Q95G + S184E, L210T + VI 721 + N213M or L210T + V172I + Q95G + G136A + T169Q + S184E. In a particular embodiment, the esterase comprises one combination of substitutions selected from L210T + VI 721 + Q95G, L210T + VI 721 + Q95G + S184E or L210T + VI 721 + N213M and exhibits both an increased degrading activity and an increased thermostability as compared to the esterase of SEQ ID N° 1.

In another particular embodiment, the esterase further comprises at least one substitution at position selected from A2, D233 or S255. Particularly, the esterase further comprises at least one substitution selected from A2E, D233N or S255A.

In an embodiment, the esterase further comprises the combination of substitution A2E + L210F + D233N + S255A. Preferably, the esterase comprises the combination of substitutions R205C + S251C + A2E + L210F + D233N + S255A. In an embodiment, the esterase comprises the combination of substitutions R205C + S251C + A2E + L210T/A/R/W/H + D233N + S255A. In an embodiment, the esterase comprises an amino acid sequence consisting of the amino acid sequence set forth in SEQ ID N°1 with the combination of substitutions R205C + S251C + A2E + L210T/A/R/W/H + D233N + S255A.

In an embodiment, the esterase comprises at least one combination of substitutions selected from L210 + V172 + Q95 + A2 + D233 + S255, L210 + V172 + Q95 + S184 + A2 + D233 + S255, L210 + V172 + N213 + A2 + D233 + S255 or L210 + V172 + Q95 + G136 + T169 + SI 84 + A2 + D233 + S255. Particularly, the esterase comprises at least one combination of substitutions selected from L210T + V172I + Q95G + A2E + D233N + S255A, L210T + V172I + Q95G + S184E+ A2E + D233N + S255A, L210T + V172I + N213M + A2E + D233N + S255A or L210T + V172I + Q95G + G136A + T169Q + S184E + A2E + D233N + S255A.

In a preferred embodiment, the esterase of the invention comprises at least one amino acid residue selected from S131, D177 and H209, as in the parent esterase, i.e. the esterase of the invention is not modified at one, two or all of these positions. Preferably, the esterase comprises the combination S131 + D177 + H209 as in the parent esterase. Alternatively, or in addition, the esterase comprises at least one amino acid residue selected from C242 or C257 as in the parent esterase. Preferably the esterase comprises the combination C242 + C257 as in the parent esterase. More preferably, the esterase comprises the combination S131 + D177 + H209 + C242 + C257 as in the parent esterase. In an embodiment, the esterase further comprises the amino acid residue P215, as in the parent esterase.

It is another object of the invention to provide an esterase which (i) has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the full length amino acid sequence set forth in SEQ ID N°l, (ii) contains at least one substitution at position L210, wherein the position is numbered by reference to the amino acid sequence set forth in SEQ ID N°l, and wherein the substitution is different from L210F. In an embodiment, the esterase comprises at least a substitution among L210A/C D/E/G/H/I/K/M/N/P/Q/R/S/T/V/W/Y. In an embodiment, the esterase comprises at least a substitution among L210A/C/D/E/G/H/K/M/N/P/Q/R/S/T/V/W/Y. In a preferred embodiment, the esterase comprises at least a substitution among L210T/A/R/W/H. Preferably, the esterase comprises at least the substitution L210T.

Particularly, the esterase comprises a substitution among L210T/A/R and exhibits an increased degrading activity as compared to the esterase of SEQ ID N°l . In another particular embodiment, the esterase comprises a substitution among L210T/W/H and exhibits an increased thermostability as compared to the esterase of SEQ ID N°l . Preferably, the esterase comprises the substitution L210T and exhibits both an increased degrading activity and an increased thermostability as compared to the esterase of SEQ ID N° 1.

In a preferred embodiment, the esterase of the invention comprises at least one amino acid residue selected from S131, D177 and H209, as in the parent esterase, i.e. the esterase of the invention is not modified at one, two or all of these positions. Preferably, the esterase comprises the combination S131 + D177 + H209 as in the parent esterase. Alternatively, or in addition, the esterase comprises at least one amino acid residue selected from C242 or C257 as in the parent esterase. Preferably the esterase comprises the combination C242 + C257 as in the parent esterase. More preferably, the esterase comprises the combination S131 + D177 + H209 + C242 + C257 as in the parent esterase. In an embodiment, the esterase further comprises the amino acid residue P215, as in the parent esterase.

In a particular embodiment, the esterase of the invention further comprises at least one amino acid substitution at a position selected from T12, E13, S14, S15, 116, E17, A18, V19, R20, R32, A35, F38, G62, F63, T64, A65, G66, Q67, E68, S69, 170, A71, W72, P75, R76, D88, T89, R92, L93, D94, Q95, P96, D97, H130, M132, G133, S139, W156, T158, R159, V172, Q175, T178, 1179, A180, P 181 , S184, F189, L204, R205, G206, A207, S208, V211, S212, N213, T214, P215, D216, T217, T218, T219, A220, K221, Y222, Q239, F240, L241, P243, A244, P245, D246, D247, F248, A249, 1250, S251, G136 or T169. Particularly, the esterase of the invention further comprises at least one amino acid substitution at a position selected from T12, E13, S14, S15, 116, E17, A18, V19, R20, R32, A35, F38, G62, F63, T64, A65, G66, Q67, E68, S69, 170, A71, W72, P75, R76, D88, T89, R92, L93, D94, Q95, P96, D97, H130, M132, G133, S139, W156, T158, R159, V172, Q175, T178, 1179, A180, P181, S184, F189, L204, R205, G206, A207, S208, V211, S212, N213, T214, P215, D216, T217, T218, T219, A220, K221, Y222, Q239, F240, L241, P243, A244, P245, D246, D247, F248, A249, 1250 or S251.

Particularly, the esterase further comprises a least one substitution at a position corresponding to residues selected from R32, A35 or F38. Alternatively, or in addition, the esterase further comprises at least one substitution at a position corresponding to residues selected from Q175, 1179, R205, G206 or S251. Particularly, the esterase comprises a least one substitution at position Q175 and exhibits an increased degrading activity as compared to the esterase of SEQ ID N°l, and/or the esterase comprises a least one substitution at a position selected from 1179 or G206 and exhibits an increased thermostability as compared to the esterase of SEQ ID N° 1. Preferably, the esterase further comprises a combination of substitutions at position R205 + S251, preferably R205C + S251C and exhibits an increased thermostability as compared to the esterase of SEQ ID N° 1.

Particularly, the esterase of the invention further comprises at least one amino acid substitution at a position selected from G136 or T169. Preferably, the esterase further comprises at least one amino acid substitution selected from G136A or T169Q.

In an embodiment, the esterase further comprises at least one substitution at position selected from T64, E68, Q95, V172, N213, P215, G136, S184 or T169. Preferably, the esterase comprises at least one substitution selected from T64M, E68T, Q95G/P, V172I, N213D/M, P215D, G136A, S184E or T169Q. Particularly, the esterase further comprises at least one substitution at position selected from T64, E68, Q95, V172, N213 or P215, preferably selected from T64M, E68T, Q95G/P, VI 721 or N213D/M.

In an embodiment, the esterase comprises at least the substitution selected from L210T/A/R/W/H and at least one substitution at position V172, preferably V172I. Preferably, the esterase comprises at least a combination of substitutions selected from L210T/A/R/W/H + VI 721, more preferably L210T + VI 721.

In a particular embodiment, the esterase comprises at least a combination of substitutions selected from L210T/A/R/W/H + VI 721 and at least one substitution at position selected from Q95, N213, G136, T169 or S184, preferably selected from Q95G/P, N213D/M, G136A, T169Q or S184E.

In an embodiment, the esterase comprises at least a substitution selected from L210T/A/R/W/H and at least one combination of substitutions at position VI 72 + Q95, VI 72 + Q95 + SI 84, V172 + N213 or V172 + Q95 + G136 + T169 + S184. Particularly, the esterase comprises at least one combination of substitutions selected from L210T + VI 721 + Q95G, L210T + VI 721 + Q95G + S184E, L210T + V172I + N213M or L210T + V172I + Q95G + G136A + T169Q + S184E.

In an embodiment, the esterase further comprises at least one substitution at position selected from A2, D233 or S255. Preferably, the esterase comprises at least one substitution selected from A2E, D233N or S255A, preferably the combination of substitutions A2E + D233N + S255A.

Particularly, the esterase comprises at least one combination of substitutions selected from L210T + V172I + Q95G + A2E + D233N + S255A, L210T + V172I + Q95G + S184E+ A2E + D233N + S255A, L210T + V172I + N213M + A2E + D233N + S255A or L210T + V172I + Q95G + G136A + T169Q + S184E+ A2E + D233N + S255A.

It is an object of the invention to provide an esterase which (i) has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the full length amino acid sequence set forth in SEQ ID N°l, (ii) contains at least one amino acid substitution selected from L210 A/ C/D/E/ G/EEI/K/M/N/P/ Q/R/ S/T / V/W / Y, R205C, S251C, Q95G/P, G136A, T169Q, V172I, S184E or N213M/D, wherein the position is numbered by reference to the amino acid sequence set forth in SEQ ID N°l, and (iii) has an increased degrading activity and/or an increased thermostability as compared to the esterase of SEQ ID N°l . In an embodiment, the esterase comprises at least one amino acid substitution selected from L210 A/C/D/E/G/H/I/K/M/N/P/Q/R/S/T/V/W/Y, R205C or S251C, preferably selected from L210 A/ C/D/E/ G/H/K/M/N/P/ Q/R/ S/T/V/W / Y, R205C or S251C. In a preferred embodiment, the esterase comprises at least amino acid substitution selected from L210T/A/R/W/H, R205C or S251C.

In an embodiment, the esterase comprises at least one amino acid substitution selected from Q95G/P, G136A, T169Q, VI 721, S184E or N213M/D, preferably selected from Q95G, VI 721, S184E or N213M.

In an embodiment, the esterase comprises at least one amino acid substitution selected from L210T/A/R/W/H, R205C, S251C, Q95G/P, G136A, T169Q, VI 721, S184E or N213M/D. Preferably, the esterase of the invention contains at least one substitution or combination of substitutions selected from L210T/A/R/W/H, R205C + S251C, Q95G, G136A, T169Q, VI 721, S184E or N213M, preferably selected from L210T/A/R/W/H and R205C + S251C, more preferably selected from L210T and R205C + S251C. Particularly, the esterase of the invention contains at least the combination of substitutions L210T/A/R/W/H + R205C + S251C. Preferably, the esterase of the invention comprises the combination L210T + R205C + S251C.

In a preferred embodiment, the esterase of the invention comprises at least one amino acid residue selected from S131, D177 and H209, as in the parent esterase, i.e. the esterase of the invention is not modified at one, two or all of these positions. Preferably, the esterase comprises the combination S131 + D177 + H209 as in the parent esterase. Alternatively, or in addition, the esterase comprises at least one amino acid residue selected from C242 or C257 as in the parent esterase. Preferably the esterase comprises the combination C242 + C257 as in the parent esterase. More preferably, the esterase comprises the combination S131 + D177 + H209 + C242 + C257 as in the parent esterase.

In an embodiment, the esterase further comprises the amino acid residue P215, as in the parent esterase.

In a particular embodiment, the esterase of the invention further comprises at least one amino acid substitution at a position selected from T12, E13, S14, S15, 116, E17, A18, V19, R20, R32, A35, F38, G62, F63, T64, A65, G66, Q67, E68, S69, 170, A71, W72, P75, R76, D88, T89, R92, L93, D94, P96, D97, H130, M132, G133, S139, W156, T158, R159, Q175, T178, 1179, A180, P 181, , FI 89, L204, G206, A207, S208, V211, S212, , T214, P215, D216, T217, T218, T219, A220, K221, Y222, Q239, F240, L241, P243, A244, P245, D246, D247, F248, A249, 1250, G136 or T169. Particularly, the esterase of the invention further comprises at least one amino acid substitution at a position selected from T12, E13, S14, S15, 116, E17, A18, V19, R20, R32, A35, F38, G62, F63, T64, A65, G66, Q67, E68, S69, 170, A71, W72, P75, R76, D88, T89, R92, L93, D94, Q95, P96, D97, H130, M132, G133, S139, W156, T158, R159, V172, Q175, T178, 1179, A180, P181, S184, F189, L204, G206, A207, S208, V211, S212, N213, T214, P215, D216, T217, T218, T219, A220, K221, Y222, Q239, F240, L241, P243, A244, P245, D246, D247, F248, A249 or 1250.

Particularly, the esterase comprises a least one substitution at a position corresponding to residues selected from R32, A35 or F38. Alternatively or in addition, the esterase comprises at least one substitution at a position corresponding to residues selected from Q175, 1179, or G206. Particularly, the esterase comprises a least a substitution at position Q175 and exhibits an increased activity as compared to the esterase of SEQ ID N°l, and/or the esterase comprises a least one substitution at a position selected from 1179 or G206 and exhibits an increased thermostability as compared to the esterase of SEQ ID N° 1.

In an embodiment, the esterase further comprises at least one substitution at position selected from T64, E68, Q95, VI 72, N213, P215, G136, S I 84 or T169, preferably selected from T64, E68, Q95, V172, N213 or P215. Particularly, the esterase comprises at least one substitution selected from T64M, E68T, Q95G/P, V172I, N213D/M, P215D, G136A, S184E or T169Q, preferably selected from T64M, E68T, Q95G/P, V172I or N213D/M, more preferably selected from T64M, E68T, Q95G, VI 721 or N213M.

In an embodiment, the esterase comprises a least two substitutions selected from L210 A/C/D/E/ G/FEI/K/M/N/P/ Q/R/ S/T/V/W /Y, R205C, S251C, Q95G/P, G136A, T169Q, VI 721, S184E orN213M/D, preferably selected from L210T/A/R/W/H, R205C, S251C, Q95G, G136A, T169Q, V172I, S184E or N213M. Preferably, the esterase comprises at least two substitutions or combination of substitutions selected from L210T/A/R/W/H, R205C + S251C, Q95G, G136A, T169Q, V172I, S184E or N213M.

In an embodiment, the esterase comprises at least the substitution selected from L210T/A/R/W/H and at least one substitution at position V172, preferably V172I. Preferably, the esterase comprises at least a combination of substitutions selected from L210T/A/R/W/H + VI 721, more preferably L210T + VI 721.

In a particular embodiment, the esterase comprises at least a combination of substitutions selected from L210T/A/R/W/H + VI 721 and at least one substitution at position selected from Q95, N213, G136, T169 or S184, preferably selected from Q95G/P, N213D/M, G136A, T169Q or S184E. In an embodiment, the esterase comprises at least a substitution selected from L210T/A/R/W/H and at least one combination of substitutions at positions VI 72 + Q95, VI 72 + Q95 + SI 84, V172 + N213 or V172 + Q95 + G136 + T169 + S184.

In an embodiment, the esterase comprises at least one combination of substitutions selected from R205C + S251C, L210T + VI 721 + Q95G, L210T + VI 721 + Q95G + S184E, L210T + VI 721 + N213M or L210T + V172I + Q95G + G136A + T169Q + S184E. In an embodiment, the esterase comprises one combination of substitutions selected from L210T + V172I + Q95G, L210T + V172I + Q95G + S184E or L210T + VI 721 + N213M and exhibits both an increased degrading activity and an increased thermostability as compared to the esterase of SEQ ID N° 1.

In an embodiment, the esterase further comprises at least one substitution at position selected from A2, D233 or S255. Preferably, the esterase comprises at least one substitution selected from A2E, D233N or S255A, preferably the combination of substitutions A2E + D233N + S255A.

Particularly, the esterase comprises at least one combination of substitutions selected from L210T + VI 721 + Q95G + A2E + D233N + S255A, L210T + V172I + Q95G + S184E+ A2E + D233N + S255A, L210T + V172I + N213M + A2E + D233N + S255A or L210T + V172I + Q95G + G136A + T169Q + S184E+ A2E + D233N + S255A.

Polyester degrading activity of the variant

It is an object of the invention to provide new enzymes having an esterase activity. In a particular embodiment, the enzyme of the invention exhibits a cutinase activity.

In a particular embodiment, the esterase of the invention has a polyester degrading activity, preferably a polyethylene terephthalate (PET) degrading activity, and/or a polybutylene adipate terephthalate (PBAT) degrading activity and/or a polycaprolactone (PCL) degrading activity and/or a polybutylene succinate (PBS) activity, more preferably a polyethylene terephthalate (PET) degrading activity, and/or a polybutylene adipate terephthalate (PBAT) degrading activity. Even more preferably, the esterase of the invention has a polyethylene terephthalate (PET) degrading activity.

Advantageously, the esterase of the invention exhibits a polyester degrading activity at least in a range of temperatures from 20°C to 90°C, preferably from 40°C to 80°C, more preferably from 60°C to 70°C. In a particular embodiment, the esterase exhibits a polyester degrading activity at 60°C. In a particular embodiment, the esterase exhibits a polyester degrading activity at 70°C. In a particular embodiment, the polyester degrading activity is still measurable at a temperature between 70°C and 80°C.

In a particular embodiment, the esterase of the invention has an increased polyester degrading activity at a given temperature, compared to the esterase of SEQ ID N°l, and more particularly at a temperature between 40°C and 80°C, more preferably between 50°C and 70°C.

In a particular embodiment, the esterase has a polyester degrading activity at 65°C at least 5% higher than the polyester degrading activity of the esterase of SEQ ID N°l, preferably at least 10%, 20%, 50%, 100% or more.

In a particular embodiment, the esterase of the invention exhibits a measurable esterase activity at least in a range of pH from 5 to 11, preferably in a range of pH from 6 to 9, more preferably in a range of pH from 6.5 to 9, even more preferably in a range of pH from 6.5 to 8.

Nucleic acids, expression cassette, vector, host cell

It is a further object of the invention to provide a nucleic acid encoding an esterase as defined above.

As used herein, the term " nucleic acid", “ nucleic sequence ,” “polynucleotide” , “ oligonucleotide” and“ nucleotide sequence” refer to a sequence of deoxyribonucleotides and/or ribonucleotides. The nucleic acids can be DNA (cDNA or gDNA), RNA, or a mixture thereof. It can be in single stranded form or in duplex form or a mixture thereof. It can be of recombinant, artificial and/or synthetic origin and it can comprise modified nucleotides, comprising for example a modified bond, a modified purine or pyrimidine base, or a modified sugar. The nucleic acids of the invention can be in isolated or purified form, and made, isolated and/or manipulated by techniques known per se in the art, e.g., cloning and expression of cDNA libraries, amplification, enzymatic synthesis or recombinant technology. The nucleic acids can also be synthesized in vitro by well-known chemical synthesis techniques, as described in, e.g., Belousov (1997) Nucleic Acids Res. 25:3440-3444.

The invention also encompasses nucleic acids which hybridize, under stringent conditions, to a nucleic acid encoding an esterase as defined above. Preferably, such stringent conditions include incubations of hybridization filters at about 42° C for about 2.5 hours in 2 X SSC/0.1%SDS, followed by washing of the filters four times of 15 minutes in 1 X SSC/0.1% SDS at 65° C. Protocols used are described in such reference as Sambrook et al. (Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor N.Y. (1988)) and Ausubel (Current Protocols in Molecular Biology (1989)).

The invention also encompasses nucleic acids encoding an esterase of the invention, wherein the sequence of said nucleic acids, or a portion of said sequence at least, has been engineered using optimized codon usage.

Alternatively, the nucleic acids according to the invention may be deduced from the sequence of the esterase according to the invention and codon usage may be adapted according to the host cell in which the nucleic acids shall be transcribed. These steps may be carried out according to methods well known to one skilled in the art and some of which are described in the reference manual Sambrook et al. (Sambrook et ah, 2001).

Nucleic acids of the invention may further comprise additional nucleotide sequences, such as regulatory regions, i.e., promoters, enhancers, silencers, terminators, signal peptides and the like that can be used to cause or regulate expression of the polypeptide in a selected host cell or system.

The present invention further relates to an expression cassette comprising a nucleic acid according to the invention operably linked to one or more control sequences that direct the expression of said nucleic acid in a suitable host cell.

The term " expression ", as used herein, refers to any step involved in the production of a polypeptide including, but being not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

The term“ expression cassette” denotes a nucleic acid construct comprising a coding region, i.e. a nucleic acid of the invention, and a regulatory region, i.e. comprising one or more control sequences, operably linked.

Typically, the expression cassette comprises, or consists of, a nucleic acid according to the invention operably linked to a control sequence such as transcriptional promoter and/or transcription terminator. The control sequence may include a promoter that is recognized by a host cell or an in vitro expression system for expression of a nucleic acid encoding an esterase of the present invention. The promoter contains transcriptional control sequences that mediate the expression of the enzyme. The promoter may be any polynucleotide that shows transcriptional activity in the host cell including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell. The control sequence may also be a transcription terminator, which is recognized by a host cell to terminate transcription. The terminator is operably linked to the 3 '-terminus of the nucleic acid encoding the esterase. Any terminator that is functional in the host cell may be used in the present invention. Typically, the expression cassette comprises, or consists of, a nucleic acid according to the invention operably linked to a transcriptional promoter and a transcription terminator.

The invention also relates to a vector comprising a nucleic acid or an expression cassette as defined above.

As used herein, the terms“vector” or " expression vector " refer to a DNA or RNA molecule that comprises an expression cassette of the invention, used as a vehicle to transfer recombinant genetic material into a host cell. The major types of vectors are plasmids, bacteriophages, viruses, cosmids, and artificial chromosomes. The vector itself is generally a DNA sequence that consists of an insert (a heterologous nucleic acid sequence, transgene) and a larger sequence that serves as the“backbone” of the vector. The purpose of a vector which transfers genetic information to the host is typically to isolate, multiply, or express the insert in the target cell. Vectors called expression vectors (expression constructs) are specifically adapted for the expression of the heterologous sequences in the target cell, and generally have a promoter sequence that drives expression of the heterologous sequences encoding a polypeptide. Generally, the regulatory elements that are present in an expression vector include a transcriptional promoter, a ribosome binding site, a terminator, and optionally present operator. Preferably, an expression vector also contains an origin of replication for autonomous replication in a host cell, a selectable marker, a limited number of useful restriction enzyme sites, and a potential for high copy number. Examples of expression vectors are cloning vectors, modified cloning vectors, specifically designed plasmids and viruses. Expression vectors providing suitable levels of polypeptide expression in different hosts are well known in the art. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. Preferably, the expression vector is a linear or circular double stranded DNA molecule.

It is another object of the invention to provide a host cell comprising a nucleic acid, an expression cassette or a vector as described above. The present invention thus relates to the use of a nucleic acid, expression cassette or vector according to the invention to transform, transfect or transduce a host cell. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which it must be introduced.

According to the invention, the host cell may be transformed, transfected or transduced in a transient or stable manner. The expression cassette or vector of the invention is introduced into a host cell so that the cassette or vector is maintained as a chromosomal integrant or as a self- replicating extra-chromosomal vector. The term "host cell" also encompasses any progeny of a parent host cell that is not identical to the parent host cell due to mutations that occur during replication. The host cell may be any cell useful in the production of a variant of the present invention, e.g., a prokaryote or a eukaryote. The prokaryotic host cell may be any Gram -positive or Gram-negative bacterium. The host cell may also be an eukaryotic cell, such as a yeast, fungal, mammalian, insect or plant cell. In a particular embodiment, the host cell is selected from the group of Escherichia coli, Bacillus, Streptomyces, Trichoderma, Aspergillus, Saccharomyces, Pichia, Vibrio or Yarrowia.

The nucleic acid, expression cassette or expression vector according to the invention may be introduced into the host cell by any method known by the skilled person, such as electroporation, conjugation, transduction, competent cell transformation, protoplast transformation, protoplast fusion, biolistic "gene gun" transformation, PEG-mediated transformation, lipid-assisted transformation or transfection, chemically mediated transfection, lithium acetate-mediated transformation, liposome-mediated transformation.

Optionally, more than one copy of a nucleic acid, cassette or vector of the present invention may be inserted into a host cell to increase production of the variant.

In a particular embodiment, the host cell is a recombinant microorganism. The invention indeed allows the engineering of microorganisms with improved capacity to degrade polyester containing material. For instance, the sequence of the invention may be used to complement a wild type strain of a fungus or bacterium already known as able to degrade polyester, in order to improve and/or increase the strain capacity.

Production of esterase

It is another object of the invention to provide a method of producing an esterase of the invention, comprising expressing a nucleic acid encoding the esterase and optionally recovering the esterase.

In particular, the present invention relates to in vitro methods of producing an esterase of the present invention comprising (a) contacting a nucleic acid, cassette or vector of the invention with an in vitro expression system; and (b) recovering the esterase produced. In vitro expression systems are well-known by the person skilled in the art and are commercially available.

Preferably, the method of production comprises (a) culturing a host cell that comprises a nucleic acid encoding an esterase of the invention under conditions suitable to express the nucleic acid; and optionally

(b) recovering said esterase from the cell culture.

Advantageously, the host cell is a recombinant Bacillus , recombinant E. coli, recombinant Aspergillus , recombinant Trichoderma, recombinant Streptomyces, recombinant Saccharomyces, recombinant Pichia, recombinant Vibrio or recombinant Yarrowia.

The host cells are cultivated in a nutrient medium suitable for production of polypeptides, using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, or small-scale or large-scale fermentation (including continuous, batch, fed- batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the enzyme to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium, from commercial suppliers or prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection).

If the esterase is excreted into the nutrient medium, the esterase can be recovered directly from the culture supernatant. Conversely, the esterase can be recovered from cell lysates or after permeabilisation. The esterase may be recovered using any method known in the art. For example, the esterase may be recovered from the nutrient medium by conventional procedures including, but not limited to, collection, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation. Optionally, the esterase may be partially or totally purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction to obtain substantially pure polypeptides.

The esterase may be used as such, in purified form, either alone or in combinations with additional enzymes, to catalyze enzymatic reactions involved in the degradation and/or recycling of polyester(s) and/or polyester containing material, such as plastic products containing polyester. The esterase may be in soluble form, or on solid phase. In particular, it may be bound to cell membranes or lipid vesicles, or to synthetic supports such as glass, plastic, polymers, filter, membranes, e.g., in the form of beads, columns, plates and the like.

Composition

It is a further object of the invention to provide a composition comprising an esterase, or a host cell of the invention, or extract thereof. In the context of the invention, the term“composition” encompasses any kind of compositions comprising an esterase or host cell of the invention. The composition of the invention may comprise from 0.1% to 99.9%, preferably from 0.1% to 50%, more preferably from 0.1% to 30%, even more preferably from 0.1% to 5% by weight of esterase, based on the total weight of the composition. Alternatively, the composition may comprise between 5 and 10% by weight of esterase of the invention.

The composition may be liquid or dry, for instance in the form of a powder. In some embodiments, the composition is a lyophilisate.

The composition may further comprise excipients and/or reagents etc. Appropriate excipients encompass buffers commonly used in biochemistry, agents for adjusting pH, preservatives such as sodium benzoate, sodium sorbate or sodium ascorbate, conservatives, protective or stabilizing agents such as starch, dextrin, arabic gum, salts, sugars e.g. sorbitol, trehalose or lactose, glycerol, polyethyleneglycol, polypropylene glycol, propylene glycol, sequestering agent such as EDTA, reducing agents, amino acids, a carrier such as a solvent or an aqueous solution, and the like. The composition of the invention may be obtained by mixing the esterase with one or several excipients.

In a particular embodiment, the composition comprises from 0.1% to 99.9%, preferably from 50% to 99.9%, more preferably from 70% to 99.9%, even more preferably from 95% to 99.9% by weight of excipient(s), based on the total weight of the composition. Alternatively, the composition may comprise from 90% to 95% by weight of excipient(s).

In a particular embodiment, the composition may further comprise additional polypeptide(s) exhibiting an enzymatic activity. The amounts of esterase of the invention will be easily adapted by those skilled in the art depending e.g., on the nature of the polyester to degrade and/or the additional enzymes/polypeptides contained in the composition.

In a particular embodiment, the esterase of the invention is solubilized in an aqueous medium together with one or several excipients, especially excipients which are able to stabilize or protect the polypeptide from degradation. For instance, the esterase of the invention may be solubilized in water, eventually with additional components, such as glycerol, sorbitol, dextrin, starch, glycol such as propanediol, salt, etc. The resulting mixture may then be dried so as to obtain a powder. Methods for drying such mixture are well known to the one skilled in the art and include, without limitation, lyophilisation, freeze-drying, spray-drying, supercritical drying, down-draught evaporation, thin-layer evaporation, centrifugal evaporation, conveyer drying, fluidized bed drying, drum drying or any combination thereof. In a particular embodiment, the composition is under powder form and comprises esterase and a stabilizing/solubilizing amount of glycerol, sorbitol or dextrin, such as maltodextrine and/or cyclodextrine, starch, glycol such as propanediol, and/or salt.

In a particular embodiment, the composition of the invention comprises at least one recombinant cell expressing an esterase of the invention, or an extract thereof. An“ extract of a ceir designates any fraction obtained from a cell, such as cell supernatant, cell debris, cell walls, DNA extract, enzymes or enzyme preparation or any preparation derived from cells by chemical, physical and/or enzymatic treatment, which is essentially free of living cells. Preferred extracts are enzymatically-active extracts. The composition of the invention may comprise one or several recombinant cells of the invention or extract thereof, and optionally one or several additional cells.

In an embodiment, the composition consists or comprises a culture medium of a recombinant microorganism expressing and excreting an esterase of the invention. In a particular embodiment, the composition comprises such culture medium lyophilized.

Uses of esterase

It is a further object of the invention to provide methods using an esterase of the invention for degrading and/or recycling in aerobic or anaerobic conditions polyester, or polyester containing material. The esterases of the invention are particularly useful for degrading PET and PET containing material.

It is therefore an object of the invention to use an esterase of the invention, or corresponding recombinant cell or extract thereof, or composition for the enzymatic degradation of a polyester.

In a particular embodiment, the polyester targeted by the esterase is selected from polyethylene terephthalate (PET), polytrimethylene terephthalate (PTT), polybutylene terephthalate (PBT), polyethylene isosorbide terephthalate (PEIT), polylactic acid (PLA), polyhydroxyalkanoate (PHA), polybutylene succinate (PBS), polybutylene succinate adipate (PBS A), polybutylene adipate terephthalate (PBAT), polyethylene furanoate (PEF), polycaprolactone (PCL), poly(ethylene adipate) (PEA), polyethylene naphthalate (PEN) and blends/mixtures of these materials, preferably polyethylene terephthalate.

In a preferred embodiment, the polyester is PET, and at least monomers (e.g., monoethylene glycol or terephthalic acid), and/or oligomers (e.g., methyl-2-hydroxyethyl terephthalate (MHET), bis(2 -hydroxy ethyl) terephthalate (BHET), 1 -(2 -Hydroxy ethyl) 4-methyl terephthalate (HEMT) and dimethyl terephthalate (DMT)) are recovered.

It is also an object of the invention to use an esterase of the invention, or corresponding recombinant cell or extract thereof, or composition for the enzymatic degradation of at least one polyester of a polyester containing material.

It is another object of the invention to provide a method for degrading at least one polyester of a polyester containing material, wherein the polyester containing material is contacted with an esterase or host cell or extract thereof or composition of the invention, thereby degrading the at least one polyester of a polyester containing material.

Advantageously, polyester(s) is (are) depolymerized up to monomers and/or oligomers.

Particularly, the invention provides a method for degrading PET of a PET containing material, wherein the PET containing material is contacted with an esterase or host cell or composition of the invention, thereby degrading the PET.

In an embodiment, at least one polyester is degraded into repolymerizable monomers and/or oligomers, which may be advantageously retrieved in order to be reused. The retrieved monomers/oligomers may be used for recycling (e.g., repolymerizing polyesters) or methanization. In a particular embodiment, at least one polyester is PET, and monoethylene glycol, terephthalic acid, methyl-2-hydroxyethyl terephthalate (MHET), bis(2 -hydroxy ethyl) terephthalate (BHET), 1 -(2 -Hydroxy ethyl) 4-methyl terephthalate (HEMT) and/or dimethyl terephthalate (DMT) are retrieved.

In an embodiment, polyester(s) of the polyester containing material is (are) fully degraded.

The time required for degrading a polyester containing material may vary depending on the polyester containing material itself (i.e., nature and origin of the polyester containing material, its composition, shape etc.), the type and amount of esterase used, as well as various process parameters (i.e., temperature, pH, additional agents, etc.). One skilled in the art may easily adapt the process parameters to the polyester containing material and the envisioned degradation time.

Advantageously, the degrading process is implemented at a temperature comprised between 20°C and 90°C, preferably between 40°C and 80°C, more preferably between 60°C and 70°C. In a particular embodiment, the degrading process is implemented at 60°C. In another particular embodiment, the degrading process is implemented at 65°C. In another particular embodiment, the degrading process is implemented at 70°C. More generally, the temperature is maintained below an inactivating temperature, which corresponds to the temperature at which the esterase is inactivated (i.e., has lost more than 80% of activity as compared to its activity at its optimum temperature) and/or the recombinant microorganism does no more synthesize the esterase. Particularly, the temperature is maintained below the glass transition temperature (Tg) of the targeted polyester.

Advantageously, the process is implemented in a continuous flow process, at a temperature at which the esterase can be used several times and/or recycled.

Advantageously, the degrading process is implemented at a pH comprised between 5 and 11, preferably at a pH between 6 and 9, more preferably at a pH between 6.5 and 9, even more preferably at a pH between 6.5 and 8.

In a particular embodiment, the polyester containing material may be pretreated prior to be contacted with the esterase, in order to physically change its structure, so as to increase the surface of contact between the polyester and the esterase.

It is another object of the invention to provide a method of producing monomers and/or oligomers from a polyester containing material, comprising exposing a polyester containing material to an esterase of the invention, or corresponding recombinant cell or extract thereof, or composition, and optionally recovering monomers and/or oligomers.

Monomers and/or oligomers resulting from the depolymerization may be recovered, sequentially or continuously. A single type of monomers and/or oligomers or several different types of monomers and/or oligomers may be recovered, depending on the starting polyester containing material.

The method of the invention is particularly useful for producing monomers selected from monoethylene glycol and terephthalic acid, and/or oligomers selected from methyl-2- hydroxy ethyl terephthalate (MHET), bis(2 -hydroxy ethyl) terephthalate (BHET), l-(2- Hydroxyethyl) 4-methyl terephthalate (HEMT) and dimethyl terephthalate (DMT), from PET, and/or plastic product comprising PET.

The recovered monomers and/or oligomers may be further purified, using all suitable purifying methods and conditioned in a re-polymerizable form. Examples of purifying methods include stripping process, separation by aqueous solution, steam selective condensation, filtration and concentration of the medium after the bioprocess, separation, distillation, vacuum evaporation, extraction, electrodialysis, adsorption, ion exchange, precipitation, crystallization, concentration and acid addition dehydration and precipitation, nanofiltration, acid catalyst treatment, semi continuous mode distillation or continuous mode distillation, solvent extraction, evaporative concentration, evaporative crystallization, liquid/liquid extraction, hydrogenation, azeotropic distillation process, adsorption, column chromatography, simple vacuum distillation and microfiltration, combined or not.

Recovered repolymerizable monomers and/or oligomers may be reused for instance to synthesize polyesters. Advantageously, polyesters of same nature are repolymerized. However, it is possible to mix the recovered monomers and/or oligomers with other monomers and/or oligomers, in order for instance to synthesize new copolymers. Alternatively, the recovered monomers may be used as chemical intermediates in order to produce new chemical compounds of interest.

The invention also relates to a method of surface hydrolysis or surface functionalization of a polyester containing material, comprising exposing a polyester containing material to an esterase of the invention, or corresponding recombinant cell or extract thereof, or composition. The method of the invention is particularly useful for increasing hydrophilicity, or water absorbency, of a polyester material. Such increased hydrophilicity may have particular interest in textiles production, electronics and biomedical applications.

It is a further object of the invention to provide a polyester containing material in which an esterase of the invention and/or a recombinant microorganism expressing and excreting said esterase is/are included. As an example, processes for preparing such polyester containing material including an esterase of the invention are disclosed in the patent applications WO2013/093355, WO 2016/198650, WO 2016/198652, WO 2019/043145 and WO 2019/043134.

It is thus an object of the invention to provide a polyester containing material containing an esterase of the invention and/or a recombinant cell and/or a composition or extract thereof and at least PET. According to an embodiment, the invention provides a plastic product comprising PET and an esterase of the invention having a PET degrading activity.

It is thus another object of the invention to provide a polyester containing material containing an esterase of the invention and/or a recombinant cell and/or a composition or extract thereof and at least PBAT. According to an embodiment, the invention provides a plastic product comprising PBAT and an esterase of the invention having a PBAT degrading activity. It is thus another object of the invention to provide a polyester containing material containing an esterase of the invention and/or a recombinant cell and/or a composition or extract thereof and at least PBS. According to an embodiment, the invention provides a plastic product comprising PBS and an esterase of the invention having a PBS degrading activity.

It is thus another object of the invention to provide a polyester containing material containing an esterase of the invention and/or a recombinant cell and/or a composition or extract thereof and at least PCL. According to an embodiment, the invention provides a plastic product comprising PCL and an esterase of the invention having a PCL degrading activity.

Classically, an esterase of the invention may be used in detergent, food, animal feed, paper making, textile and pharmaceutical applications. More particularly, the esterase of the invention may be used as a component of a detergent composition. Detergent compositions include, without limitation, hand or machine laundry detergent compositions, such as laundry additive composition suitable for pre-treatment of stained fabrics and rinse added fabric softener composition, detergent composition for use in general household hard surface cleaning operations, detergent compositions for hand or machine dishwashing operations. In a particular embodiment, an esterase of the invention may be used as a detergent additive. The invention thus provides detergent compositions comprising an esterase of the invention. Particularly, the esterase of the invention may be used as a detergent additive in order to reduce pilling and greying effects during textile cleaning.

The present invention is also directed to methods for using an esterase of the invention in animal feed, as well as to feed compositions and feed additives comprising an esterase of the invention. The terms“feed” and“feed composition” refer to any compound, preparation, mixture, or composition suitable for, or intended for intake by an animal. In another particular embodiment, the esterase of the invention is used to hydrolyze proteins, and to produce hydrolysates comprising peptides. Such hydrolysates may be used as feed composition or feed additives.

It is a further object of the invention to provide a method for using an esterase of the invention in papermaking industry. More particularly, the esterase of the invention may be used to remove stickies from the paper pulp and water pipelines of paper machines.

EXAMPLES

Example 1 -Construction, expression and purification of esterases Construction

Esterase according to the invention have been generated using the plasmidic construction pET26b-220/5-His. This plasmid consists in cloning a gene encoding the esterase of SEQ ID N°l, optimized for Escherichia coli expression between Ndel and Xhol restriction sites. Two site directed mutagenesis kits have been used according to the recommendations of the supplier, in order to generate the esterase variants: QuikChange II Site-Directed Mutagenesis kit and QuikChange Lightning Multi Site-Directed from Agilent (Santa Clara, California, USA). Expression and purification of the esterases

The strains Stellar™ (Clontech, California, USA) and E. coli One Shot® BL21 DE3 (Life technologies, Carlsbad, California, USA) have been successively employed to perform the cloning and recombinant expression in 50 mL LB-Miller medium or ZYM auto inducible medium (Studier et al ., 2005- Prot. Exp. Pur. 41, 207-234). The induction in LB-Miller medium has been performed at 16°C, with 0.5 mM of isopropyl b-D-l-thiogalactopyranoside (IPTG, Euromedex, Souffelweyersheim, France). The cultures have been stopped by centrifugation (8000 rpm, 20 minutes at 10°C) in an Avanti J-26 XP centrifuge (Beckman Coulter, Brea, USA). The cells have been suspended in 20 mL of Talon buffer (Tris-HCl 20 mM, NaCl 300 mM, pH 8). Cell suspension was then sonicated during 2 minutes with 30% of amplitude (2sec ON and lsec OFF cycles) by FB 705 sonicator (Fisherbrand, Illkirch, France). Then, a step of centrifugation has been realized: 30 minutes at 11000 rpm, 10°C in an Eppendorf centrifuge. The soluble fraction has been collected and submitted to affinity chromatography. This purification step has been completed with Talon® Metal Affinity Resin (Clontech, CA, USA). Protein elution has been carried out with steps of Talon buffer supplemented with imidazole. Purified protein has been dialyzed against Talon buffer then quantified using Bio-Rad protein assay according to manufacturer instructions (Lifescience Bio-Rad, France) and stored at +4°C.

Example 2 - Evaluation of the degrading activity of the esterases

The degrading activity of the esterases has been determined and compared to the activity of esterase of SEQ ID N° 1.

Multiple methodologies to assess the specific activity have been used:

(1) Specific activity based upon PET hydrolysis

(2) Activity based upon the degradation of a polyester under solid form

(3) Activity based upon PET hydrolysis in reactors above 100 mL 2.1. Specific activity based upon PET hydrolysis

100 mg of amorphous PET under powder form (prepared according to WO 2017/198786 to reach a crystallinity below 20%) were weighted and introduced in a 100 mL glass bottle. 1 mL of esterase preparation comprising esterase of SEQ ID N°1 (as reference control) or esterase of the invention, prepared at 0.02 mg/mL in Talon buffer (Tris-HCl 20 mM, NaCl 0.3M, pH 8) were introduced in the glass bottle. Finally, 49 mL of 0.1 M potassium phosphate buffer pH 8 were added.

The depolymerization started by incubating each glass bottle at 60°C, 65°C or 70°C and 150 rpm in a Max Q 4450 incubator (Thermo Fisher Scientific, Inc. Waltham, MA, USA).

The initial rate of depolymerization reaction, in mg of equivalent TA generated / hour, was determined by samplings performed at different time during the first 24 hours and analyzed by Ultra High Performance Liquid Chromatography (UHPLC). If necessary, samples were diluted in 0.1 M potassium phosphate buffer pH 8. Then, 150 pL of methanol and 6.5 pL of HC1 6 N were added to 150 pL of sample or dilution. After mixing and filtering on 0.45 pm syringe filter, samples were loaded on UHPLC to monitor the liberation of terephthalic acid (TA), MHET and BHET. Chromatography system used was an Ultimate 3000 UHPLC system (Thermo Fisher Scientific, Inc. Waltham, MA, USA) including a pump module, an autosampler, a column oven thermostated at 25°C, and an UV detector at 240 nm. The column used was a Discovery® HS Cl 8 HPLC Column (150 x 4.6 mm, 5 pm, equipped with precolumn, Supelco, Bellefonte, USA). TA, MHET and BHET were separated using a gradient of MeOH (30 % to 90 %) in 1 mM of H2SO4 at lmL/min. Injection was 20 pL of sample. TA, MHET and BHET were measured according to standard curves prepared from commercial TA and BHET and in house synthetized MHET in the same conditions than samples. The specific activity of PET hydrolysis (mg of equivalent TA/hour/mg of enzyme) was determined in the linear part of the hydrolysis curve of the reaction, such curve being set up by samplings performed at different time during the first 24 hours. Equivalent TA corresponds to the sum of TA measured and of TA contained in measured MHET and BHET.

2.2. Activity based upon degradation of a polyester under solid form

20 pL of enzyme preparation was deposited in a well created in an agar plate containing PET. Preparation of agar plates was realized by solubilizing 500mg of PET in hexafluoro-2 -propanol (HFIP), and pouring this medium in a 250 mL aqueous solution. After HFIP evaporation at 52°C under 140 mbar, the solution was mixed v/v with 0.2 M potassium phosphate buffer pH 8 containing 3% agar. Around 30 mL of the mixture is used to prepare each plate and stored at 4°C.

The diameters or the surface area of the halos formed due to the polyester degradation by wild- type esterase and variants were measured and compared after 2 to 24 hours at 60 °C, 65°C or 70°C.

2.3. Activity based upon PET hydrolysis in reactor

From 0.69 pmol to 2.07 pmol of purified esterase prepared in 80mL of 100 mM potassium phosphate buffer pH 8 were mixed with 20 g amorphous PET (prepared according to WO 2017/198786 to reach a crystallinity below 20%) in a 500 mL Minibio bioreactor (Applikon Biotechnology, Delft, The Netherlands). Temperature regulation at 60°C, 65°C or 70°C was performed by water bath immersion and a single marine impeller was used to maintain constant agitation at 250 rpm. The pH of the PET depolymerization assay was regulated at pH 8 by 6N NaOH and was assured by my-Control bio controller system (Applikon Biotechnology, Delft, The Netherlands). Base consumption was recorded during the assay and may be used for the characterization of the PET depolymerization assay.

The final yield of the PET depolymerization assay was determined either by the determination of residual PET weight or by the determination of equivalent TA generated, or through the base consumption. Weight determination of residual PET was assessed by the filtration, at the end of the reaction, of the reactional volume through a 12 to 15 pm grade 11 ashless paper filter (Dutscher SAS, Brumath, France) and drying of such retentate before weighting it. The determination of equivalent TA generated was realized using EIHPLC methods described in 2.1, and the percentage of hydrolysis was calculated based on the ratio of molar concentration at a given time (TA + MHET + BHET) versus the total amount of TA contained in the initial sample. PET depolymerization produced acid monomers that will be neutralized with the base to be able to maintain the pH in the reactor. The determination of equivalent TA produced was calculating using the corresponding molar base consumption, and the percentage of hydrolysis was calculated based on the ratio of molar concentration at a given time of equivalent TA versus the total amount of TA contained in the initial sample.

Specific degrading activity of esterases (variants) of the invention are shown in Table 1 below. The specific degrading activity of the esterase of SEQ ID N°1 is used as a reference and considered as 100% specific degrading activity. The specific degrading activity is measured as exposed in Example 2.1 at 65°C. Table 1 : Specific degrading activity of variants of the invention

Example 3 - Evaluation of the thermostability of esterases of the invention

The thermostability of esterases of the invention has been determined and compared to the thermostability of the esterase of SEQ ID N° 1.

Different methodologies have been used to estimate thermostability:

(1) Circular dichroism of proteins in solution;

(2) Residual esterase activity after protein incubation in given conditions of temperatures, times and buffers;

(3) Residual polyester’s depolymerization activity after protein incubation in given conditions of temperatures, times and buffers;

(4) Ability to degrade a solid polyester compound (such as PET or PBAT or analogues) dispersed in an agar plate, after protein incubation in given conditions of temperatures, times and buffers;

(5) Ability to perform multiple rounds of polyester’s depolymerization assays in given conditions of temperatures, buffers, protein concentrations and polyester concentrations;

(6) Differential Scanning Fluorimetry (DSF);

Details on the protocol of such methods are given below.

3.1 Circular dichroism

Circular dichroism (CD) has been performed with a Jasco 815 device (Easton, USA) to compare the melting temperature (T _m ) of the esterase of SEQ ID N°1 (Tm=79.8°C) with the Tm of the esterases of the invention. Technically 400 pL protein sample was prepared at 0.5 mg / mL in Talon buffer and used for CD. A first scan from 280 to 190 nm was realized to determine two maxima intensities of CD corresponding to the correct folding of the protein. A second scan was then performed from 25°C to 110°C, at length waves corresponding to such maximal intensities and providing specific curves (sigmoid 3 parameters y=a/(l+e ^A ((x-x0)/b))) that were analyzed by Sigmaplot version 11.0 software, the Tm is determined when x=x0. The T _m obtained reflects the thermostability of the given protein. The higher the T _m is, the more stable the variant is at high temperature.

3.2 Residual esterase activity

1 mL of a solution of 40 mg/L (in Talon buffer) of the esterase of SEQ ID N°1 or of an esterase of the invention was incubated at different temperatures (40, 50, 60, 65, 70, 75, 80 and 90°C) up to 10 days. Regularly, a sample, was taken, diluted 1 to 500 times in a 0.1M potassium phosphate buffer pH 8.0 and para nitro phenol -butyrate (pNP-B) assay was realized. 20 pL of sample are mixed with 175pL of 0.1M potassium phosphate buffer pH 8.0 and 5pL of pNP-B solution in 2-methyl-2 butanol (40 mM). Enzymatic reaction was performed at 30°C under agitation, during 15 minutes and absorbance at 405 nm was acquired by microplate spectrophotometer (Versamax, Molecular Devices, Sunnyvale, CA, USA). Activity of pNP-B hydrolysis (initial velocity expressed in pmol of pNPB/min) was determined using a standard curve for the liberated para nitro phenol in the linear part of the hydrolysis curve.

3.3 Residual polyester depolymerizing activity

10 mL of a solution of 40 mg/L (in Talon buffer) of the esterase of SEQ ID N°1 and of an esterase of the invention respectively were incubated at different temperatures (40, 50, 60, 65, 70, 75, 80 and 90°C) during 1 to 30 days. Regularly, a 1 mL sample was taken, and transferred into a bottle containing 100 mg of amorphous PET (prepared according to WO 2017/198786 to reach a crystallinity below 20%) micronized at 250-500 pm and 49 mL of 0.1M potassium phosphate buffer pH 8.0 and incubated at 60°C, 65°C or 70°C. 150 pL of buffer were sampled regularly. When required, samples were diluted in 0.1 M potassium phosphate buffer pH 8. Then, 150 pL of methanol and 6.5 pL of HC1 6 N were added to 150 pL of sample or dilution. After mixing and filtering on 0.45 pm syringe filter, samples were loaded on UHPLC to monitor the liberation of terephthalic acid (TA), MHET and BHET. Chromatography system used was an Ultimate 3000 UHPLC system (Thermo Fisher Scientific, Inc. Waltham, MA, USA) including a pump module, an autosampler, a column oven thermostated at 25°C, and an UV detector at 240 nm. The column used was a Discovery® HS C18 HPLC Column (150 x 4.6 mm, 5 pm, equipped with precolumn, Supelco, Bellefonte, USA). TA, MHET and BHET were separated using a gradient of MeOH (30 % to 90 %) in 1 mM of H2SO4 at lmL/min. Injection was 20 pL of sample. TA, MHET and BHET were measured according to standard curves prepared from commercial TA and BHET and in house synthetized MHET in the same conditions than samples. Activity of PET hydrolysis (pmol of PET hydrolysed/min or mg of equivalent TA produced/hour) was determined in the linear part of the hydrolysis curve, such curve being set up by samplings performed at different time during the first 24 hours. Equivalent TA corresponds to the sum of TA measured and of TA contained in measured MHET and BHET.

3.4 Degradation of a polyester under solid form

1 mL of a solution of 40 mg/L (in Talon buffer) of the esterase of SEQ ID N° 1 and of an esterase of the invention respectively were incubated at different temperatures (65, 70, 75, 80 and 90°C) during 1 to 30 days. Regularly, 20 pL of enzyme preparation was deposited in a well created in an agar plate containing PET. Preparation of agar plates containing PET was realized by solubilizing 500mg of PET in hexafluoro-2 -propanol (HFIP), and pouring this medium in a 250 mL aqueous solution. After HFIP evaporation at 52°C under 140 mbar, the solution was mixed v/v with 0.2 M potassium phosphate buffer pH 8 containing 3% agar. Around 30 mL of the mixture is used to prepare each omnitray and stored at 4°C.

The diameter or the surface area of the halos formed due to the polyester degradation by wild- type esterase and variants of the invention were measured and compared after 2 to 24 hours at 60°C, 65°C or 70°C. The half-life of the enzyme at a given temperature corresponds to the time required to decrease by a 2-fold factor the diameter of the halo.

3.5 Multiple rounds of polyester’s depolymerization

The ability of the esterase to perform successive rounds of polyester’s depolymerization assays was evaluated in an enzymatic reactor. A Minibio 500 bioreactor (Applikon Biotechnology B.V., Delft, The Netherlands) was started with 3 g of amorphous PET (prepared according to WO 2017/198786 to reach a crystallinity below 20%) and 100 mL of 10 mM potassium phosphate buffer pH 8 containing 3 mg of LC-esterase. Agitation was set at 250 rpm using a marine impeller. Bioreactor was thermostated at 60°C, 65°C or 70°C by immersion in an external water bath. pH was regulated at 8 by addition of KOH at 3 M. The different parameters (pH, temperature, agitation, addition of base) were monitored thanks to BioXpert software V2.95. 1.8 g of amorphous PET (prepared according to WO 2017/198786 to reach a crystallinity below 20%) were added every 20 h. 500 pL of reaction medium was sampled regularly.

Amount of TA, MHET and BHET was determined by HPLC, as described in example 2.3. Amount of EG was determined using an Aminex HPX-87K column (Bio-Rad Laboratories, Inc, Hercules, California, United States) thermostated at 65°C. Eluent was K2HPO4 5 mM at 0.6 mL.min ¹ . Injection was 20 mE. Ethylene glycol was monitored using refractometer.

The percentages of hydrolysis were calculated based on the ratio of molar concentration at a given time (TA +MHET + BHET) versus the total amount of TA contained in the initial sample, or based on the ratio of molar concentration at a given time (EG +MHET + 2 x BHET) versus the total amount of EG contained in the initial sample. Rate of degradation is calculated in mg of total liberated TA per hour or in mg of total EG per hour.

Half-life of enzyme was evaluated as the incubation time required to obtain a loss of 50 % of the degradation rate.

3.6 Differential Scanning Fluorimetry (DSF)

DSF was used to evaluate the thermostability of the wild-type protein (SEQ ID N°l) and variants thereof by determining their melting temperature (Tm), temperature at which half of the protein population is unfolded. Protein samples were prepared at a concentration of 14 mM and stored in buffer A consisting of 20 mM Tris HC1 pH 8.0, 300 mM NaCl. The SYPRO orange dye 5000x stock solution in DMSO was first diluted to 250x in water. Protein samples were loaded onto a white clear 96-well PCR plate (Bio-Rad cat# HSP9601) with each well containing a final volume of 25 mΐ. The final concentration of protein and SYPRO Orange dye in each well were 5 mM (0.14 mg/ml) and 10X respectively. Loaded volumes per well were as follow: 15 pL of buffer A, 9 pL of the 14pM protein solution and 1 pL of the 250x Sypro Orange diluted solution. The PCR plates were then sealed with optical quality sealing tape and spun at 2000 rpm for 1 min at room temperature. DSF experiments were then carried out using a CFX96 real-time PCR system set to use the 450/490 excitation and 560/ 580 emission filters. The samples were heated from 25 to 100°C at the rate of 0.3°C/second. A single fluorescence measurement was taken every 0.03 second. Melting temperatures were determined from the peak(s) of the first derivatives of the melting curve using the Bio-Rad CFX Manager software.

Esterase of SEQ ID N°1 and esterases of the invention were then compared based on their Tm values. Due to high reproducibility between experiments on the same protein from different productions, a ATm of 0.8°C was considered as significant to compare variants. Tm values correspond to the average of at least 3 measurements. Tm of the esterase of SEQ ID N°1 is evaluated at 79.8°C as exposed in Example 3.6.

Thermostabilities of esterase variants of the invention are shown in Table 2 below, expressed in Tm values and evaluated according to Example 3.6. The gain of Tm as compared to the esterase of SEQ ID N°1 is indicated in brackets. Table 2: Tm of the esterases of the invention compared to SEQ ID N° 1